Purpose: To report long term results of biologic treatment of severe and refractory Behçet’s uveitis (BU) choosing a different biologic agent according to the uveitis clinical features. Methods: Retrospective cohort of patients with BU refractory to conventional therapy, who received Interferon (IFN) alpha-2a or Infliximab (IFX) for at least 3 months. Results: Twenty-two patients were included (mean age 29 ± 10 years, 63% males); Fifteen received IFN and 7 IFX, for a mean treatment period of 30 ± 24(SD) months. Twenty (90%) patients discontinued treatment, in most cases for complete remission (77%). Seven patients (32%) showed relapses during treatment and five (23%) after discontinuation. Visual acuity improved significantly in IFN group and all eyes showed a significant decrease in central macular thickness at 12 months. Conclusions: Both IFX and IFN Alpha-2a were effective and well tolerated in the treatment of refractory BU using a customized approach based on the uveitis features.

Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features / De Simone, L.; Invernizzi, A.; Aldigeri, R.; Mastrofilippo, V.; Marvisi, C.; Gozzi, F.; Bolletta, E.; Adani, C.; Pipitone, N.; Muratore, F.; Fontana, L.; Salvarani, C.; Cimino, L.. - In: OCULAR IMMUNOLOGY AND INFLAMMATION. - ISSN 0927-3948. - (2020), p. 1-9. [10.1080/09273948.2020.1815797]

Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features

Aldigeri R.;
2020

Abstract

Purpose: To report long term results of biologic treatment of severe and refractory Behçet’s uveitis (BU) choosing a different biologic agent according to the uveitis clinical features. Methods: Retrospective cohort of patients with BU refractory to conventional therapy, who received Interferon (IFN) alpha-2a or Infliximab (IFX) for at least 3 months. Results: Twenty-two patients were included (mean age 29 ± 10 years, 63% males); Fifteen received IFN and 7 IFX, for a mean treatment period of 30 ± 24(SD) months. Twenty (90%) patients discontinued treatment, in most cases for complete remission (77%). Seven patients (32%) showed relapses during treatment and five (23%) after discontinuation. Visual acuity improved significantly in IFN group and all eyes showed a significant decrease in central macular thickness at 12 months. Conclusions: Both IFX and IFN Alpha-2a were effective and well tolerated in the treatment of refractory BU using a customized approach based on the uveitis features.
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features / De Simone, L.; Invernizzi, A.; Aldigeri, R.; Mastrofilippo, V.; Marvisi, C.; Gozzi, F.; Bolletta, E.; Adani, C.; Pipitone, N.; Muratore, F.; Fontana, L.; Salvarani, C.; Cimino, L.. - In: OCULAR IMMUNOLOGY AND INFLAMMATION. - ISSN 0927-3948. - (2020), p. 1-9. [10.1080/09273948.2020.1815797]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2885249
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 6
social impact